Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Dow
Fish and Richardson
Cerilliant
Farmers Insurance
Mallinckrodt
McKesson
Citi
Boehringer Ingelheim

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RIFAXIMIN

« Back to Dashboard

Clinical Trials for Rifaximin

Trial ID Title Status Sponsor Phase Summary
NCT00098384 Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea Completed The University of Texas Health Science Center, Houston Phase 2 The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
NCT00098384 Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea Completed Valeant Pharmaceuticals International, Inc. Phase 2 The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
NCT00098384 Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea Completed DuPont, Hurbert L., MD Phase 2 The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
NCT00259155 Rifaximin for the Treatment of Irritable Bowel Syndrome Completed University of Chicago Phase 2 We have recently shown that the majority of patients with irritable bowel syndrome (IBS) have an abnormal lactulose breath test to suggest the presence of bacterial overgrowth of the small intestine. In open label and double blind treatment of IBS subjects with antibiotics, a dramatic improvement in clinical symptoms are observed. In these studies, the antibiotic chosen was neomycin, which is noted to have an efficacy of 20-25% in normalizing the lactulose breath test. A more efficacious antibiotic is needed. Therefore the aim of this study is to determine the efficacy of rifaximin in normalizing the lactulose breath test in IBS subjects with concomitant improvement in clinical symptoms.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Rifaximin

Condition Name

Condition Name for Rifaximin
Intervention Trials
Hepatic Encephalopathy 17
Liver Cirrhosis 13
Irritable Bowel Syndrome 8
Cirrhosis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rifaximin
Intervention Trials
Hepatic Encephalopathy 24
Brain Diseases 24
Liver Cirrhosis 19
Fibrosis 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rifaximin

Trials by Country

Trials by Country for Rifaximin
Location Trials
United States 368
China 10
Italy 9
Mexico 7
United Kingdom 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rifaximin
Location Trials
California 21
New York 20
Florida 15
Virginia 14
Texas 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rifaximin

Clinical Trial Phase

Clinical Trial Phase for Rifaximin
Clinical Trial Phase Trials
Phase 4 22
Phase 3 26
Phase 2/Phase 3 7
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rifaximin
Clinical Trial Phase Trials
Completed 46
Recruiting 37
Not yet recruiting 13
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rifaximin

Sponsor Name

Sponsor Name for Rifaximin
Sponsor Trials
Valeant Pharmaceuticals International, Inc. 31
Institute of Liver and Biliary Sciences, India 4
Shanghai Zhongshan Hospital 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rifaximin
Sponsor Trials
Other 138
Industry 44
U.S. Fed 14
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Dow
McKinsey
Accenture
Merck
Colorcon
Queensland Health
AstraZeneca
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.